The global Next Generation Cancer Diagnostics market was valued at US$ 6198.2 million in 2023 and is anticipated to reach US$ 20950 million by 2030, witnessing a CAGR of 18.5% during the forecast period 2024-2030.

Next Generation Cancer Diagnostics Market

North American market for Next Generation Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Next Generation Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Next Generation Cancer Diagnostics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Next Generation Cancer Diagnostics include Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health and Myriad Genetics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Next Generation Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next Generation Cancer Diagnostics.

Report Scope

The Next Generation Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Next Generation Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Next Generation Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Next Generation Cancer Diagnostics Market Report

Report Metric	Details
Report Name	Next Generation Cancer Diagnostics Market
Accounted market size in 2023	US$ 6198.2 million
Forecasted market size in 2030	US$ 20950 million
CAGR	18.5%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Next Generation Sequencing qPCR & Multiplexing DNA Microarrays Others
Segment by Application	Hospitals Clinics Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, GE Healthcare, PerkinElmer, Genomic Health, Illumina, Hologic, Almac Group, Janssen Global Services, Sysmex Corporation
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next Generation Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Next Generation Cancer Diagnostics Market growing?

Ans: The Next Generation Cancer Diagnostics Market witnessing a CAGR of 18.5% during the forecast period 2024-2030.

What is the Next Generation Cancer Diagnostics Market size in 2030?

Ans: The Next Generation Cancer Diagnostics Market size in 2030 will be US$ 20950 million.

Who are the main players in the Next Generation Cancer Diagnostics Market report?

Ans: The main players in the Next Generation Cancer Diagnostics Market are Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, GE Healthcare, PerkinElmer, Genomic Health, Illumina, Hologic, Almac Group, Janssen Global Services, Sysmex Corporation

What are the Application segmentation covered in the Next Generation Cancer Diagnostics Market report?

Ans: The Applications covered in the Next Generation Cancer Diagnostics Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Next Generation Cancer Diagnostics Market report?

Ans: The Types covered in the Next Generation Cancer Diagnostics Market report are Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Next Generation Sequencing

1.2.3 qPCR & Multiplexing

1.2.4 DNA Microarrays

1.2.5 Others

1.3 Market by Application

1.3.1 Global Next Generation Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Next Generation Cancer Diagnostics Market Perspective (2019-2030)

2.2 Next Generation Cancer Diagnostics Growth Trends by Region

2.2.1 Global Next Generation Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Next Generation Cancer Diagnostics Historic Market Size by Region (2019-2024)

2.2.3 Next Generation Cancer Diagnostics Forecasted Market Size by Region (2025-2030)

2.3 Next Generation Cancer Diagnostics Market Dynamics

2.3.1 Next Generation Cancer Diagnostics Industry Trends

2.3.2 Next Generation Cancer Diagnostics Market Drivers

2.3.3 Next Generation Cancer Diagnostics Market Challenges

2.3.4 Next Generation Cancer Diagnostics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Next Generation Cancer Diagnostics Players by Revenue

3.1.1 Global Top Next Generation Cancer Diagnostics Players by Revenue (2019-2024)

3.1.2 Global Next Generation Cancer Diagnostics Revenue Market Share by Players (2019-2024)

3.2 Global Next Generation Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Next Generation Cancer Diagnostics Revenue

3.4 Global Next Generation Cancer Diagnostics Market Concentration Ratio

3.4.1 Global Next Generation Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Next Generation Cancer Diagnostics Revenue in 2023

3.5 Next Generation Cancer Diagnostics Key Players Head office and Area Served

3.6 Key Players Next Generation Cancer Diagnostics Product Solution and Service

3.7 Date of Enter into Next Generation Cancer Diagnostics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Next Generation Cancer Diagnostics Breakdown Data by Type

4.1 Global Next Generation Cancer Diagnostics Historic Market Size by Type (2019-2024)

4.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2025-2030)

5 Next Generation Cancer Diagnostics Breakdown Data by Application

5.1 Global Next Generation Cancer Diagnostics Historic Market Size by Application (2019-2024)

5.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Next Generation Cancer Diagnostics Market Size (2019-2030)

6.2 North America Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Next Generation Cancer Diagnostics Market Size by Country (2019-2024)

6.4 North America Next Generation Cancer Diagnostics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Next Generation Cancer Diagnostics Market Size (2019-2030)

7.2 Europe Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Next Generation Cancer Diagnostics Market Size by Country (2019-2024)

7.4 Europe Next Generation Cancer Diagnostics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Next Generation Cancer Diagnostics Market Size (2019-2030)

8.2 Asia-Pacific Next Generation Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2019-2024)

8.4 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Next Generation Cancer Diagnostics Market Size (2019-2030)

9.2 Latin America Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Next Generation Cancer Diagnostics Market Size by Country (2019-2024)

9.4 Latin America Next Generation Cancer Diagnostics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Next Generation Cancer Diagnostics Market Size (2019-2030)

10.2 Middle East & Africa Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2019-2024)

10.4 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Cepheid

11.1.1 Cepheid Company Detail

11.1.2 Cepheid Business Overview

11.1.3 Cepheid Next Generation Cancer Diagnostics Introduction

11.1.4 Cepheid Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.1.5 Cepheid Recent Development

11.2 Koninklijke Philips N.V

11.2.1 Koninklijke Philips N.V Company Detail

11.2.2 Koninklijke Philips N.V Business Overview

11.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Introduction

11.2.4 Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.2.5 Koninklijke Philips N.V Recent Development

11.3 F. Hoffmann-La Roche Ltd

11.3.1 F. Hoffmann-La Roche Ltd Company Detail

11.3.2 F. Hoffmann-La Roche Ltd Business Overview

11.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Introduction

11.3.4 F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.3.5 F. Hoffmann-La Roche Ltd Recent Development

11.4 Qiagen

11.4.1 Qiagen Company Detail

11.4.2 Qiagen Business Overview

11.4.3 Qiagen Next Generation Cancer Diagnostics Introduction

11.4.4 Qiagen Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.4.5 Qiagen Recent Development

11.5 Novartis AG

11.5.1 Novartis AG Company Detail

11.5.2 Novartis AG Business Overview

11.5.3 Novartis AG Next Generation Cancer Diagnostics Introduction

11.5.4 Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.5.5 Novartis AG Recent Development

11.6 Abbott

11.6.1 Abbott Company Detail

11.6.2 Abbott Business Overview

11.6.3 Abbott Next Generation Cancer Diagnostics Introduction

11.6.4 Abbott Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.6.5 Abbott Recent Development

11.7 Thermo Fisher Scientific

11.7.1 Thermo Fisher Scientific Company Detail

11.7.2 Thermo Fisher Scientific Business Overview

11.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Introduction

11.7.4 Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.7.5 Thermo Fisher Scientific Recent Development

11.8 Opko Health

11.8.1 Opko Health Company Detail

11.8.2 Opko Health Business Overview

11.8.3 Opko Health Next Generation Cancer Diagnostics Introduction

11.8.4 Opko Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.8.5 Opko Health Recent Development

11.9 Myriad Genetics

11.9.1 Myriad Genetics Company Detail

11.9.2 Myriad Genetics Business Overview

11.9.3 Myriad Genetics Next Generation Cancer Diagnostics Introduction

11.9.4 Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.9.5 Myriad Genetics Recent Development

11.10 Agilent Technologies

11.10.1 Agilent Technologies Company Detail

11.10.2 Agilent Technologies Business Overview

11.10.3 Agilent Technologies Next Generation Cancer Diagnostics Introduction

11.10.4 Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.10.5 Agilent Technologies Recent Development

11.11 GE Healthcare

11.11.1 GE Healthcare Company Detail

11.11.2 GE Healthcare Business Overview

11.11.3 GE Healthcare Next Generation Cancer Diagnostics Introduction

11.11.4 GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.11.5 GE Healthcare Recent Development

11.12 PerkinElmer

11.12.1 PerkinElmer Company Detail

11.12.2 PerkinElmer Business Overview

11.12.3 PerkinElmer Next Generation Cancer Diagnostics Introduction

11.12.4 PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.12.5 PerkinElmer Recent Development

11.13 Genomic Health

11.13.1 Genomic Health Company Detail

11.13.2 Genomic Health Business Overview

11.13.3 Genomic Health Next Generation Cancer Diagnostics Introduction

11.13.4 Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.13.5 Genomic Health Recent Development

11.14 Illumina

11.14.1 Illumina Company Detail

11.14.2 Illumina Business Overview

11.14.3 Illumina Next Generation Cancer Diagnostics Introduction

11.14.4 Illumina Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.14.5 Illumina Recent Development

11.15 Hologic

11.15.1 Hologic Company Detail

11.15.2 Hologic Business Overview

11.15.3 Hologic Next Generation Cancer Diagnostics Introduction

11.15.4 Hologic Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.15.5 Hologic Recent Development

11.16 Almac Group

11.16.1 Almac Group Company Detail

11.16.2 Almac Group Business Overview

11.16.3 Almac Group Next Generation Cancer Diagnostics Introduction

11.16.4 Almac Group Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.16.5 Almac Group Recent Development

11.17 Janssen Global Services

11.17.1 Janssen Global Services Company Detail

11.17.2 Janssen Global Services Business Overview

11.17.3 Janssen Global Services Next Generation Cancer Diagnostics Introduction

11.17.4 Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.17.5 Janssen Global Services Recent Development

11.18 Sysmex Corporation

11.18.1 Sysmex Corporation Company Detail

11.18.2 Sysmex Corporation Business Overview

11.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Introduction

11.18.4 Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2019-2024)

11.18.5 Sysmex Corporation Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Cepheid Inc

Koninklijke Philips N V

F Hoffmann La Roche Ltd

Qiagen NV

Novartis

Abbott

Thermo Fisher Scientific

Janssen Global Services

Sysmex Corporation

List of Tables

Table 1. Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Next Generation Sequencing

Table 3. Key Players of qPCR & Multiplexing

Table 4. Key Players of DNA Microarrays

Table 5. Key Players of Others

Table 6. Global Next Generation Cancer Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Next Generation Cancer Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Next Generation Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global Next Generation Cancer Diagnostics Market Share by Region (2019-2024)

Table 10. Global Next Generation Cancer Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global Next Generation Cancer Diagnostics Market Share by Region (2025-2030)

Table 12. Next Generation Cancer Diagnostics Market Trends

Table 13. Next Generation Cancer Diagnostics Market Drivers

Table 14. Next Generation Cancer Diagnostics Market Challenges

Table 15. Next Generation Cancer Diagnostics Market Restraints

Table 16. Global Next Generation Cancer Diagnostics Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global Next Generation Cancer Diagnostics Market Share by Players (2019-2024)

Table 18. Global Top Next Generation Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2023)

Table 19. Ranking of Global Top Next Generation Cancer Diagnostics Companies by Revenue (US$ Million) in 2023

Table 20. Global 5 Largest Players Market Share by Next Generation Cancer Diagnostics Revenue (CR5 and HHI) & (2019-2024)

Table 21. Key Players Headquarters and Area Served

Table 22. Key Players Next Generation Cancer Diagnostics Product Solution and Service

Table 23. Date of Enter into Next Generation Cancer Diagnostics Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Next Generation Cancer Diagnostics Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global Next Generation Cancer Diagnostics Revenue Market Share by Type (2019-2024)

Table 27. Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global Next Generation Cancer Diagnostics Revenue Market Share by Type (2025-2030)

Table 29. Global Next Generation Cancer Diagnostics Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global Next Generation Cancer Diagnostics Revenue Market Share by Application (2019-2024)

Table 31. Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global Next Generation Cancer Diagnostics Revenue Market Share by Application (2025-2030)

Table 33. North America Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 34. North America Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)

Table 35. North America Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)

Table 36. Europe Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. Europe Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)

Table 38. Europe Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)

Table 39. Asia-Pacific Next Generation Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 40. Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)

Table 41. Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)

Table 42. Latin America Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Latin America Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)

Table 44. Latin America Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)

Table 47. Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)

Table 48. Cepheid Company Detail

Table 49. Cepheid Business Overview

Table 50. Cepheid Next Generation Cancer Diagnostics Product

Table 51. Cepheid Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 52. Cepheid Recent Development

Table 53. Koninklijke Philips N.V Company Detail

Table 54. Koninklijke Philips N.V Business Overview

Table 55. Koninklijke Philips N.V Next Generation Cancer Diagnostics Product

Table 56. Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 57. Koninklijke Philips N.V Recent Development

Table 58. F. Hoffmann-La Roche Ltd Company Detail

Table 59. F. Hoffmann-La Roche Ltd Business Overview

Table 60. F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Product

Table 61. F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 62. F. Hoffmann-La Roche Ltd Recent Development

Table 63. Qiagen Company Detail

Table 64. Qiagen Business Overview

Table 65. Qiagen Next Generation Cancer Diagnostics Product

Table 66. Qiagen Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 67. Qiagen Recent Development

Table 68. Novartis AG Company Detail

Table 69. Novartis AG Business Overview

Table 70. Novartis AG Next Generation Cancer Diagnostics Product

Table 71. Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 72. Novartis AG Recent Development

Table 73. Abbott Company Detail

Table 74. Abbott Business Overview

Table 75. Abbott Next Generation Cancer Diagnostics Product

Table 76. Abbott Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 77. Abbott Recent Development

Table 78. Thermo Fisher Scientific Company Detail

Table 79. Thermo Fisher Scientific Business Overview

Table 80. Thermo Fisher Scientific Next Generation Cancer Diagnostics Product

Table 81. Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 82. Thermo Fisher Scientific Recent Development

Table 83. Opko Health Company Detail

Table 84. Opko Health Business Overview

Table 85. Opko Health Next Generation Cancer Diagnostics Product

Table 86. Opko Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 87. Opko Health Recent Development

Table 88. Myriad Genetics Company Detail

Table 89. Myriad Genetics Business Overview

Table 90. Myriad Genetics Next Generation Cancer Diagnostics Product

Table 91. Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 92. Myriad Genetics Recent Development

Table 93. Agilent Technologies Company Detail

Table 94. Agilent Technologies Business Overview

Table 95. Agilent Technologies Next Generation Cancer Diagnostics Product

Table 96. Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 97. Agilent Technologies Recent Development

Table 98. GE Healthcare Company Detail

Table 99. GE Healthcare Business Overview

Table 100. GE Healthcare Next Generation Cancer Diagnostics Product

Table 101. GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 102. GE Healthcare Recent Development

Table 103. PerkinElmer Company Detail

Table 104. PerkinElmer Business Overview

Table 105. PerkinElmer Next Generation Cancer Diagnostics Product

Table 106. PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 107. PerkinElmer Recent Development

Table 108. Genomic Health Company Detail

Table 109. Genomic Health Business Overview

Table 110. Genomic Health Next Generation Cancer Diagnostics Product

Table 111. Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 112. Genomic Health Recent Development

Table 113. Illumina Company Detail

Table 114. Illumina Business Overview

Table 115. Illumina Next Generation Cancer Diagnostics Product

Table 116. Illumina Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 117. Illumina Recent Development

Table 118. Hologic Company Detail

Table 119. Hologic Business Overview

Table 120. Hologic Next Generation Cancer Diagnostics Product

Table 121. Hologic Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 122. Hologic Recent Development

Table 123. Almac Group Company Detail

Table 124. Almac Group Business Overview

Table 125. Almac Group Next Generation Cancer Diagnostics Product

Table 126. Almac Group Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 127. Almac Group Recent Development

Table 128. Janssen Global Services Company Detail

Table 129. Janssen Global Services Business Overview

Table 130. Janssen Global Services Next Generation Cancer Diagnostics Product

Table 131. Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 132. Janssen Global Services Recent Development

Table 133. Sysmex Corporation Company Detail

Table 134. Sysmex Corporation Business Overview

Table 135. Sysmex Corporation Next Generation Cancer Diagnostics Product

Table 136. Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)

Table 137. Sysmex Corporation Recent Development

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Next Generation Cancer Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Next Generation Cancer Diagnostics Market Share by Type: 2023 VS 2030

Figure 3. Next Generation Sequencing Features

Figure 4. qPCR & Multiplexing Features

Figure 5. DNA Microarrays Features

Figure 6. Others Features

Figure 7. Global Next Generation Cancer Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Next Generation Cancer Diagnostics Market Share by Application: 2023 VS 2030

Figure 9. Hospitals Case Studies

Figure 10. Clinics Case Studies

Figure 11. Others Case Studies

Figure 12. Next Generation Cancer Diagnostics Report Years Considered

Figure 13. Global Next Generation Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Next Generation Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Next Generation Cancer Diagnostics Market Share by Region: 2023 VS 2030

Figure 16. Global Next Generation Cancer Diagnostics Market Share by Players in 2023

Figure 17. Global Top Next Generation Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Next Generation Cancer Diagnostics Revenue in 2023

Figure 19. North America Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Next Generation Cancer Diagnostics Market Share by Country (2019-2030)

Figure 21. United States Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Next Generation Cancer Diagnostics Market Share by Country (2019-2030)

Figure 25. Germany Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. France Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. U.K. Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Italy Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Russia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Nordic Countries Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Next Generation Cancer Diagnostics Market Share by Region (2019-2030)

Figure 33. China Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Japan Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. South Korea Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Southeast Asia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. India Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Australia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Next Generation Cancer Diagnostics Market Share by Country (2019-2030)

Figure 41. Mexico Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Brazil Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Next Generation Cancer Diagnostics Market Share by Country (2019-2030)

Figure 45. Turkey Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Saudi Arabia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Cepheid Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 48. Koninklijke Philips N.V Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 49. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 50. Qiagen Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 51. Novartis AG Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 52. Abbott Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 53. Thermo Fisher Scientific Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 54. Opko Health Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 55. Myriad Genetics Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 56. Agilent Technologies Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 57. GE Healthcare Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 58. PerkinElmer Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 59. Genomic Health Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 60. Illumina Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 61. Hologic Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 62. Almac Group Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 63. Janssen Global Services Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 64. Sysmex Corporation Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Colon Cancer Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-31C5944

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global CAR T-Cell Immunotherapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-10J13802

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Color Detection Sensors Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-6G9623

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Appendix Cancer Treatment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-2H1312

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions